Nonalcoholic Fatty Liver Disease: Indian Perspective.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

25 citing papers in PubMed.

1. Saroglitazar and vitamin E vs. lifestyle interventions in metabolic dysfunction associated steatotic liver disease: A 3-arm randomised study.The Indian journal of medical research · 2026
   Trial
2. Saroglitazar for non-obese metabolic-dysfunction associated steatotic liver disease (MASLD): An open-label randomised controlled trial.The Indian journal of medical research · 2026
   Trial
3. Understanding regional differences in MASLD: the Indian perspective.npj metabolic health and disease · 2026
   Article
4. Perspectives of Indian Gastroenterologists and Hepatologists on Nonalcoholic Fatty Liver Disease Diagnosis and Management: Insights From the Nationwide Web-Based Cross-Sectional DRIVE Survey.Interactive journal of medical research · 2026
   Article
5. Toxins to treatments: Impact of environmental pollutants, gut microbiota, and natural compounds on non-alcoholic fatty liver disease progression.World journal of hepatology · 2025
   Review
6. Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease: Mapping Across Different Indian Populations (MAP Study).Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
   Article
7. Role of serum endotoxin, FGF19, TLR2, TNF-α, IL-12 and IL-10 in NAFLD-associated T2DM pathogenesis: Insights into Th1 bias and protective mechanisms.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025
   Article
8. Assessment of dietary, genetic and metabolic factors in South Indian adolescents with metabolic dysfunction-associated steatotic liver disease: a case-control study protocol.BMJ paediatrics open · 2025
   Article
9. The Impact of Sira Vedha (Phlebotomy) at the Right Elbow Joint in the Treatment of Non-Alcoholic Fatty Liver Disease - A Research Report.Journal of pharmacy & bioallied sciences · 2024
   Article
10. Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions.Cureus · 2023
    Review
11. Management of liver diseases: Current perspectives.World journal of gastroenterology · 2022
    Review
12. Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions.JCO global oncology · 2022
    Review
13. Work-up for Incidentally Detected NAFLD: How Far is It Worth?Euroasian journal of hepato-gastroenterology · 2022
    Review
14. Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena.Liver research (Beijing, China) · 2022
    Review
15. Evaluation of Hepatic Steatosis and Fibrosis Using Transient Elastography in Patients With Obstructive Sleep Apnea.Journal of clinical and experimental hepatology
    Article
16. Prevalence of Non-Alcoholic Fatty Liver Disease in Urban Adult Population in a Tertiary Care Center, Chennai.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine
    Article
17. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).Journal of clinical and experimental hepatology
    Review
18. Exploring diversity in Non-Alcoholic Fatty Liver Disease (NAFLD) among lean, overweight, and obese patients: A Multicenter study from India.Nigerian medical journal : journal of the Nigeria Medical Association
    Article
19. Central Obesity is an Independent Determinant of Advanced Fibrosis in Lean Patients With Nonalcoholic Fatty Liver Disease.Journal of clinical and experimental hepatology
    Article
20. NASH After Liver Transplantation: Impact of Immunosuppression.Journal of clinical and experimental hepatology
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.